Resumé
Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95% CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | National Cancer Institute. Journal (Print) |
| ISSN | 0027-8874 |
| DOI | |
| Status | E-pub ahead of print - 5. nov. 2019 |
Fingeraftryk
Citer dette
}
Antihistamines and ovarian cancer survival : nationwide cohort study and in vitro cell viability assay. / Verdoodt, Freija; Dehlendorff, Christian; Jäättelä, Marja; Strauss, Robert; Pottegård, Anton; Hallas, Jesper; Friis, Søren; Kjaer, Susanne K.
I: National Cancer Institute. Journal (Print), 05.11.2019.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
TY - JOUR
T1 - Antihistamines and ovarian cancer survival
T2 - nationwide cohort study and in vitro cell viability assay
AU - Verdoodt, Freija
AU - Dehlendorff, Christian
AU - Jäättelä, Marja
AU - Strauss, Robert
AU - Pottegård, Anton
AU - Hallas, Jesper
AU - Friis, Søren
AU - Kjaer, Susanne K
N1 - © The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
PY - 2019/11/5
Y1 - 2019/11/5
N2 - Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95% CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.
AB - Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95% CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.
U2 - 10.1093/jnci/djz217
DO - 10.1093/jnci/djz217
M3 - Journal article
JO - National Cancer Institute. Journal (Print)
JF - National Cancer Institute. Journal (Print)
SN - 0027-8874
ER -